Trials / Completed
CompletedNCT01839630
Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China
Study on Transarterial Chemoembolization Combined With Sorafenib in Chinese Patients With Unresectable Hepatocellular Carcinoma (SUCCESS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 302 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is to obtain the characteristics and treatment pattern of the unresectable HCC patients who are candidates for systemic therapy and in whom a decision to treat with sorafenib from early stage of TACE treatment course (concomitantly use no later than the 3rd TACE procedure) has been made under real-life practice conditions.this study will also conclude the safety and effectiveness of combination in uHCC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator |
Timeline
- Start date
- 2013-05-30
- Primary completion
- 2016-08-06
- Completion
- 2016-12-29
- First posted
- 2013-04-25
- Last updated
- 2017-12-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01839630. Inclusion in this directory is not an endorsement.